Skip to main content
Device/Product name
Active Ingredient
Vonicog alfa
Date of decision
Submission type
New biological entity
ATC codes
What was the decision based on
The decision was based on quality (chemistry and manufacturing), nonclinical (pharmacology and toxicology), clinical (pharmacology, safety and efficacy) and risk management plan information submitted by the sponsor. The benefit-risk profile of Veyvondi was considered favourable for the therapeutic use approved.
What steps were involved in the decision process

Registration timeline

The following table summarises the key steps and dates for this comparable overseas regulator approach B (COR-B) application.

Description Date
Submission dossier accepted and first round evaluation commenced 3 June 2019
First round evaluation completed 30 September 2019
Sponsor provides responses on questions raised in first round evaluation 28 November 2019
Second round evaluation completed 2 January 2020
Delegate's overall benefit-risk assessment 8 April 2020
Sponsor's pre-Advisory Committee response Not applicable
Advisory Committee meeting Not applicable
Registration decision (Outcome) 15 April 2020
Completion of administrative activities and registration on ARTG 20 April 2020
Number of working days from submission dossier acceptance to registration decision* 173

* The COR-B process has a 175 working day evaluation and decision timeframe.

Date of entry onto ARTG
Original publication date
Black triangle scheme
Yes. This product will remain in the scheme for 5 years, starting on the date the product is first supplied in Australia
Dose forms
Powder and solvent for injection
650 IU, 1300 IU
Other ingredients

Powder: Sodium citrate dehydrate, Glycine, Trehalose dehydrate, Mannitol, Polysorbate 80

Solvent: Water for injections

Pack sizes
Routes of administration
Intravenous infusion

Veyvondi is not bioequivalent to plasma-derived von Willebrand factor, and individual patient dosage must be calculated specifically for Veyvondi.

Treatment of von Willebrand disease (VWD) should be supervised by a physician experienced in the treatment of haemostatic disorders.


Dosage and frequency of administration must be individualised according to clinical judgement and based on the patient's weight, severity and type of bleeding episodes/surgical intervention, as well as both von Willebrand factor ristocetin cofactor (VWF:RCo) and factor VIII coagulant activity (FVIII:C) levels, and also based on monitoring of appropriate clinical and laboratory measures. Dose based on bodyweight may require adjustment in underweight or overweight patients.

Generally, 1 IU/kg Veyvondi raises the plasma VWF:RCo by 0.02 IU/mL (2%).

Haemostasis cannot be ensured until FVIII:C is at least 0.4 IU/mL (≥ 40% of normal activity). Depending on the patient's baseline FVIII:C levels, a single infusion of recombinant von Willebrand factor (rVWF) will, in a majority of patients, lead to an increase above 40% in endogenous FVIII:C activity within 6 hours and will result in sustaining this level up to 72 hours post infusion. The dose and duration of the treatment depend on the clinical status of the patient, the severity and type of bleeding, and both VWF:RCo and FVIII:C levels. If the patient's baseline plasma FVIII:C level is < 40% or is unknown and in all situations where a rapid correction of haemostasis should be achieved, such as treatment of an acute haemorrhage, severe trauma or emergency surgery, it is necessary to administer a recombinant coagulation factor VIII (rFVIII) product with the first infusion of Veyvondi, in order to achieve a haemostatic plasma level of FVIII:C.

However, if an immediate rise in FVIII:C is not necessary, or if the baseline FVIII:C level is sufficient to ensure haemostasis, the physician may decide to omit the co-administration of rFVIII at the first infusion with Veyvondi.

In case of major bleeding events or major surgeries requiring repeated, frequent infusions, monitoring of FVIII:C levels is recommended, to decide if rFVIII is required for subsequent infusions to avoid excessive rise of FVIII:C.

Patients should be monitored for the development of VWF or FVIII neutralising antibodies (inhibitors). If suspected VWF activity (VWF:RCo) plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if a VWF or FVIII inhibitor is present. See Product Information Section 4.4 Special Warnings and Precautions for Use, Neutralising antibodies (inhibitors).

For further information refer to the Product Information.

Pregnancy category
B2Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed.Studies in animals are inadequate or may be lacking, but available data show no evidence of an increased occurrence of fetal damage.The use of any medicine during pregnancy requires careful consideration of both risks and benefits by the treating health professional. This must not be used as the sole basis of decision making in the use of medicines during pregnancy. The TGA does not provide advice on the use of medicines in pregnancy for specific cases. More information is available from obstetric drug information services in your State or Territory.
What was approved

Veyvondi (vonicog alfa) was approved for the following therapeutic use:

Veyvondi is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated, for the

  • treatment of haemorrhage and surgical bleeding
  • prevention of surgical bleeding.

Veyvondi should not be used in the treatment of Haemophilia A.

What is this medicine and how does it work
von Willebrand factor (VWF) is the carrier molecule for factor VIII (FVIII), an essential cofactor of secondary haemostasis that leads to the fibrin clot formation, and facilitates platelet adhesion to sub-endothelium at sites of vascular injury.Vonicog alfa is a recombinant human von Willebrand factor (rVWF). Vonicog alfa behaves in the same way as endogenous VWF.Administration of vonicog alfa allows correction of the haemostatic abnormalities exhibited by patients who suffer from VWF deficiency (VWD) at two levels: Vonicog alfa re-establishes platelet adhesion to the vascular sub-endothelium at the site of vascular damage (as it binds both to the vascular sub-endothelium matrix (for example, collagen) and to the platelet membrane), providing primary haemostasis as shown by the shortening of the bleeding time. This effect occurs immediately and is known to depend to a large extent on the level of polymerisation of the protein. Vonicog alfa produces delayed correction of the associated FVIII deficiency. Administered intravenously, vonicog alfa binds to endogenous FVIII (which is produced normally by the patient), and by stabilising this factor, avoids its rapid degradation. Because of this, administration of vonicog alfa restores the FVIII:C level to normal as a secondary effect. After the first infusion, the FVIII:C rises above 40% within 6 hours and peaks within 24 hours in a majority of patients, depending on the baseline FVIII:C level.The adhesive activity of rvWF depends on the size of its multimers, with ultra-large multimers being the most effective in supporting interactions with collagen and platelet receptors.
What post-market commitments will the sponsor undertake
  • Veyvondi (vonicog alfa) is to be included in the Black Triangle Scheme. The Product Information (PI) and Consumer Medicines Information (CMI) for Veyvondi must include the black triangle symbol and mandatory accompanying text for five years, which starts from the date that the sponsor notifies the TGA of supply of the product.
  • The Veyvondi European Union-Risk Management Plan (EU-RMP) (version 1.4, date 18 September 2019; data lock point (DLP) 6 March 2018), with Australian specific Annex (version 1.1, dated 10 January 2020), included with submission PM-2019-01555-1-6, and any subsequent revisions, as agreed with the TGA will be implemented in Australia.

    An obligatory component of risk management plans is routine pharmacovigilance. Routine pharmacovigilance includes the submission of periodic safety update reports (PSURs).

    Reports are to be provided in line with the current published list of EU reference dates and frequency of submission of PSURs until the period covered by such reports is not less than three years from the date of the approval letter.

    The reports are to at least meet the requirements for PSURs as described in the European Medicines Agency's Guideline on Good Pharmacovigilance Practices (GVP) Module VII-periodic safety update report (Rev 1), Part VII.B Structures and processes. Note that submission of a PSUR does not constitute an application to vary the registration.

  • Batch release testing and compliance with Certified Product Details (CPD)
    • It is a condition of registration that all batches of Veyvondi-vonicog alfa 650 IU powder for injection with solvent vials and Veyvondi-vonicog alfa 1300 IU powder for injection with solvent vials imported into/manufactured in Australia must comply with the product details and specifications approved during evaluation and detailed in the Certified Product Details (CPD).
    • It is a condition of registration that up to 5 initial batches of Veyvondi-vonicog alfa 650 IU powder for injection with solvent vials and Veyvondi-vonicog alfa 1300 IU powder for injection with solvent vials imported into/manufactured in Australia is not released for sale until samples and/or the manufacturer's release data have been assessed and endorsed for release by the TGA Laboratories Branch. Outcomes of laboratory testing are published biannually in the TGA Database of Laboratory Testing Results.
    • The sponsor should be prepared to provide product samples, reference materials and documentary evidence as defined by the TGA Laboratories branch. The sponsor must contact for specific material requirements related to the batch release testing/assessment of the product. More information on TGA testing of biological medicines is available at Testing of biological medicines.

    This batch release condition will be reviewed and may be modified on the basis of actual batch quality and consistency. This condition remains in place until the sponsor is notified in writing of any variation.

  • Certified Product Details

    The CPD, as described in Guidance 7: Certified Product Details of the Australian Regulatory Guidelines for Prescription Medicines (ARGPM), in PDF format, for the above products should be provided upon registration of these therapeutic goods. In addition, an updated CPD should be provided when changes to finished product specifications and test methods are approved in a Category 3 application or notified through a self-assessable change.

  • For all injectable products the PI must be included with the product as a package insert.

Help us improve the Therapeutic Goods Administration site